Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma

Affiliations

• ¹ Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.
• ² Institute for Animal Experimentation, Hokkaido University Faculty of Medicine, Sapporo, Japan.
• ³ Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
• ⁴ Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
• ⁵ Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan. nakagawam@med.hokudai.ac.jp.